Literature DB >> 26339719

Oral mucosal involvement and petechial lesions: a SDRIFE case with unusual findings.

Ayse Serap Karadag1, Emin Ozlu2, Necmettin Akdeniz2,3, Tugba Kevser Uzuncakmak4, Zafer Turkoglu5, Seyma Ozkanli4, Ebru Zemheri6.   

Abstract

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a type IV hypersensitivity reaction characterized by a symmetrical erythematous rash in the gluteal and intertriginous areas. SDRIFE was previously considered to be the same presentation as Baboon Syndrome, however, has been suggested to be a different entity in the recent publications. The lesions are generally maculopapular and there is no mucosal involvement. To date, no case with petechial findings and mucosal involvement has been reported in the literature. The present study reports a SDRIFE case with a symmetrical erythematous petechial rash and oral mucosal involvement after taking oral amoxicillin.

Entities:  

Keywords:  Drug eruption; SDRIFE; drug toxicity

Mesh:

Substances:

Year:  2015        PMID: 26339719     DOI: 10.3109/15569527.2015.1067227

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  3 in total

1.  First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention.

Authors:  Carl H Göbel; Axel Heinze; Sarah Karstedt; Anna Cirkel; Thomas F Münte; Hartmut Göbel
Journal:  Pain Ther       Date:  2022-07-31

2.  Drug Provocation Testing in the Diagnosis of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Induced by Clarithromycin.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Diyana Ognyanova Ogneva; Cezara Motei; Cosmina Rusu; Luiza Spiru
Journal:  Maedica (Bucur)       Date:  2021-06

3.  A Case of Intertriginous and Flexural Exanthema caused by Amoxicillin.

Authors:  Bárbara Cancela-Díez; David López-Delgado; José Aneiros-Fernandez; Ricardo Ruiz-Villaverde
Journal:  Sultan Qaboos Univ Med J       Date:  2019-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.